There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.
Rising sales of Pfizer's key new medicines and prospects that more drugs will be approved soon have analysts speculating the biggest U.S. drugmaker won't break up after all. Its adjusted earnings amounted to 64 cents per share, two cents better than analysts estimated.
Early last month, U.S. Reps. Diane Black (R-Tenn.) and Earl Blumenauer (D-Ore.)—both of whom sit on the House Ways and Means Committee's Health Subcommittee—introduced a bill that would change how the federal tax code treats high-deductible health plans that are paired with tax-exempt...
Physicians are increasingly selling their practices to larger groups to gain access to the capital and expertise needed to survive under value-based reimbursement.
A federal mandate to use unique device identifiers offers an opportunity to reduce the risk of patients being harmed by products, but the UDI system, which is being implemented over the next four years by the Food and Drug Administration, means a lot of changes— especially for the...
Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27% due to higher sales, a lower tax bill and some one-time gains. The company raised its 2016 financial forecasts, citing the strong quarter and an improved business outlook.
Pfizer subsidiary Wyeth and the government have finalized a $784.6 million settlement over allegations that Wyeth hid drug discounts to avoid paying Medicaid millions of dollars in rebates.
The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.
The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.
Allergan's stock is down nearly 20% in pre-market Tuesday trading after the U.S. announced an aggressive push in its campaign to shut down so-called tax inversions by American companies.
The Food and Drug Administration expanded approval of a Pfizer drug to treat a small subset of lung cancer patients with a rare mutation.
Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.